Browsing Tag
Divis
Can Divi’s maintain its premium valuation amid headwinds?
SynopsisIndian pharma companies have been struggling to maintain margins because of strong headwinds. Due to increased competition, pharma companies are experiencing price erosion in the…
Divi’s Laboratories rating – Add: Results beat estimates on all counts
Divi’s Laboratories’ (Divi’s) Q4FY22 performance beat our estimates across parameters. Consolidated revenues grew 40.8% y-o-y to Rs 25.2 bn, Ebitda margin improved 380bps y-o-y to 43.9% and…
Abhay Agarwal on why he added Divi’s, LTI and Lemon Tree to his portfolio now
“Instead of there being a panic, people are looking at tactical opportunities and opportunities to deploy capital,” says Abhay Agarwal, MD & CIO, Piper Serica.
What is the mood among the…
Divi’s Labs Rating ‘Hold’: Results were a slight miss on estimates
We downgrade our rating to Hold. Our PT moves from Rs 5,624 to Rs 5,563.Divi’s Q2FY22 revenue/EBITDA missed our estimates by 2%/3% but PAT was a beat on lower taxes. Pfizer’s COVID-19 oral…
Market Movers: What spurred the rally in chemical stocks, RIL and Divi’s?
MUMBAI: Despite recent doubts over their valuations and calls from some money managers to temper expectations for the sector, chemical stocks cannot stop defying gravity.
The bull market in…